Divers
Chapitre J.1
Edition en français
Traduction : Laure Woestelandt, Jordan Sibeoni Sous la direction de : Marie-Rose Moro Avec le soutien de la SFPEADA
Trastornos externalizantes
Capítulo D.1.1
Edición: Matías Irarrázaval & Andres Martin
Traductores: Fernanda Prieto-Tagle & Carlos Gómez
This study aimed to understand the patterns of HIV drug resistance in pregnant women in Mozambique. This might help in tailoring optimal regimens for prevention of mother to child transmission of HIV (pMTCT) and antenatal care.
Level of stunting among Bangladeshi children <5years declined from 51% in 2004 to 36% and underweight from 41% in 2007 to 33% (BDHS 2014). But the decrease in wasting rate is not as expected, which is only from 17% to 14.3 % over last decade. Approximately 3.1 % (BDHS 2014) of under-5 children suffe...ring from SAM only by weight-for-length or height z-score (WHZ) <-3 criterion and estimated to be a total of ~ 450,000. Because, there are no national information on prevalence of SAM using mid upper arm circumference (MUAC) and presence of bipedal oedema in under-5 children, thus the actual number of children suffering from SAM could be much higher than the current estimate.
more
National Tuberculosis Control Program; Mycobacterial Disease Control National AIDS/STD Program
No publication year indicated
The cost of newborn and child health interventions were estimated considering several different angles. At the first attempt, the cost of implementing all newborn and child health interventions packaged as antenatal, Intra natal, Essential newborn care, Care of sic...k newborn, Care of premature & LBW, Nutrition, Immunization, Care of sick infants and newborns, ECCD and WASH was estimated. This estimate reflects the cost of entire newborn and child care program thrust in the country. Costs of different intervention sub packages were also determined.
more
The strategic priorities of the CCS 2014–2018 are:
(1) Strengthening the health system.
(2) Enhancing the achievement of communicable disease control targets.
(3) Controlling the growth of the noncommunicable disease burden.
(4) Promoting health throughout the life course.
...
(5) Strengthening capacity for emergency risk management and surveillance systems for various health threats.
more
Full eHandbook under: http://www.msh.org/resources/health-systems-in-action-an-ehandbook-for-leaders-and-managers
Effective supply management has the potential to make a powerful contribution to the reliable availability of essential medicines, which are a crucial part of the delivery of highqualit...y health care services. Because medicines are costly and poor management so often results in waste, good supply management is also crucial to the cost-effectiveness of providing medicines.
more
This interim guidance to national health authorities and blood transfusion services outlines the steps required to collect convalescent whole blood (CWB) or plasma (CP) from Ebola virus disease (EVD) recovered patients for transfusion to patients with early EVD, as an empirical treatment modality.
...
Document contents:
Guidance on donor selection, screening, donation and handling of blood and plasma units;
guidance on transfusion of convalescent whole blood or plasma;
other considerations.
more
Learning from earthquake relief and recovery operations
Clinical guideline, Methods, Evidence and Recommendations
In this guideline the following is covered: information needs of people with chronic hep
titis B and their carers; where children, young people and adults with chronic hepatitis B a-
should be assessed; assessment of liver disease, includi...ng the use of non-invasive tests and genotype testing; criteria for offering antiviral treatment; the efficacy, safety and cost effectiveness of currently available treatments; selection of first-line therapy; management of treatment failure or drug resistance; prophylactic treatment during im-
munosuppressive therapy; and monitoring for treatment response
more
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
This Technical Brief focuses on current principles and approaches to Moderate Acute Malnutrition (MAM) management, highlighting key constraints, gaps in knowledge and areas still lacking consensus. It is intended to inform ongoing debates among practitioners, national partners, donors and analysts o...n what information and evidence on best practices are currently available, where the gaps are, and priorities for going forward.
more
J. European Academy of Dermatology and Venereology, 4 August 2014